Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week Observational Safety Study of Brolucizumab (Beovu) in nAMD in Japan
jRCT2031200370Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoints: Number of patients with ocular adverse events and Number of patients with non-ocular adverse events. Started Nov 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031200370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200370.